首页 › 慢性淋巴细胞白血病 › 田纳西州 › Nashville
Nashville TN 慢性淋巴细胞白血病临床试验
13项针对 慢性淋巴细胞白血病的研究正在 Nashville及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Tennessee Oncology, Pllc Nashville, Nashville
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
招募中3 期
- Tennessee Oncology, Nashville
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中3 期
- Tennessee Oncology, Pllc Nashville, Nashville
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
招募中3 期
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
招募中2 期
- SCRI Oncology Partners, Nashville
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
招募中3 期
- SCRI Oncology Partners, Nashville
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
招募中1/2 期
- SCRI Oncology Partners, Nashville
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
招募中3 期
- Sarah Cannon Research Institute SCRI, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- TriStar BMT, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- Tennessee Oncology, Nashville
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
招募中4 期
- Tennessee Oncology, Nashville
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
招募中4 期
- Tennessee Oncology, Nashville
HPC Offered for PRESERVE Expansion
招募中观察性研究
- Tristar Centennial Medical Center, Nashville
其他城市的 慢性淋巴细胞白血病试验
- Boston, MA31 项研究
- Columbus, OH28 项研究
- Durham, NC27 项研究
- Washington, DC22 项研究
- Seattle, WA20 项研究
- Rochester, MN18 项研究
- New York City, NY18 项研究
- Houston, TX17 项研究
- Baldwin Park, CA16 项研究
- Milwaukee, WI15 项研究
- Chicago, IL14 项研究
- Cincinnati, OH14 项研究
Nashville的其他研究
- 非小细胞肺癌97 项研究
- 乳腺癌81 项研究
- 转移性癌症70 项研究
- 结直肠癌69 项研究
- 癌症（所有类型）65 项研究
- 卵巢癌49 项研究
- 前列腺癌43 项研究
- 肺癌40 项研究
- 头颈鳞状细胞癌39 项研究
- 胰腺癌39 项研究
- 子宫内膜癌38 项研究
- 黑色素瘤33 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。